Repligen Corporation
corporate_fare Company Profile
Repligen Corporation (NASDAQ:RGEN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for RGEN at importance 7 or higher on its 1–10 market-impact scale.
Recent high-impact activity:
- Repligen Exceeds Q4 & Full Year 2025 Revenue Guidance, Projects Strong 2026 Growth and Margin Expansion
Financial Snapshot
Fiscal year ended December 31, 2025
Revenue
$738.26M
Net Income
$48.89M
Diluted EPS
$0.86
Op. Cash Flow
$117.42M
Free Cash Flow
$93.9M
Gross Profit
$386.25M
Operating Income
$55.17M
Cash & Equivalents
$566.02M
Total Debt
$542.21M
Debt / Equity
0.26×
Net Margin
6.6%
Shares Outstanding
56.33M sh
Source: 10-K · filed 2026-02-26 · accession 0001193125-26-076528
show_chartPrice Chart
Loading chart...
feed RGEN - Filings & News (Page 2)
RGEN
Feb 24, 2026, 7:33 AM EST
Price at Filing:
$137.29
Real-time Price:
$163.81
Change:
+$26.52 (+19%)
Market Cap:
$10.471B